In addition to the ideal in vivo effect on relapsing-remitting MA and AD,395,396 [18F]GE180 has also been applied to evaluate TSPO expression and survival rates in patients with glioma, thus suggesting that [18F]GE180 could be used to determine the prognosis of patients with recurrent glioma.397 [11C]ER176 shows high binding capacity to all TSPO rs6971 polymorphisms, as indicated by PET/CT imaging in healthy subjects with high-affinity binding (Ala/Ala), mixed-affinity binding (Ala/Thr) and low-affinity binding (Thr/Thr). The gene discussed is TSPO; the disease is glioma.